Clinical Trials Logo

Clinical Trial Summary

The main objective is to demonstrate that dTMS is more efficient than high frequency rTMS with a conventional coil. The patient will receive treatment arm A or B : Arm A : classic rTMS treatment (use of the 8-shaped coil) and standard therapy Arm B: treatment with deep rTMS (use of the H-shaped coil (helmet)) and standard therapies. 20 rTMS sessions are planned (5 sessions per week) and 3 follow-up visits : at Day 30, Day 60 and Day 90.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04956016
Study type Interventional
Source Centre Hospitalier Henri Laborit
Contact Ghina HARIKA-GERMANEAU, Dr
Phone 0033 5 16 52 61 18
Email ghina.harika-germaneau@ch-poitiers.fr
Status Recruiting
Phase N/A
Start date August 23, 2021
Completion date November 2024

See also
  Status Clinical Trial Phase
Recruiting NCT03851380 - Improving Brain Stimulation Through Imaging
Completed NCT04977674 - Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine Early Phase 1
Completed NCT03207282 - Treatment Resistant Depression in America Latina
Completed NCT02452892 - Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD) N/A
Completed NCT02691520 - Epidemiology of Treatment Resistant Depression in Taiwan Phase 4
Active, not recruiting NCT04159012 - NESBID: Neuro-Stimulation of the Brain in Depression N/A
Recruiting NCT05870501 - Synaptic Imaging and Network Activity in Treatment Resistant Depression N/A
Completed NCT04239651 - rTMS With and Without iCBT For the Treatment of Resistant Depression (TRD) N/A
Completed NCT02493868 - A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression Phase 3
Completed NCT04599855 - A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression Phase 4
Completed NCT03283670 - Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies Phase 2
Recruiting NCT03004521 - Lithium Versus Quetiapine in Treatment Resistant Depression Phase 4
Recruiting NCT04783103 - Neuromodulation in the Elderly Depressed: a Brain Imaging Pilot Study N/A
Completed NCT03434041 - A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression Phase 3
Terminated NCT03887624 - Investigate the Clinical Responses of Ethosuximide in Patients With Treatment-Resistant Depression. Early Phase 1
Completed NCT02577250 - Ketamine Infusions for PTSD and Treatment-Resistant Depression Phase 1
Recruiting NCT02610712 - Clinical Trial of the Use of Ketamine in Treatment Resistant Depression Phase 4
Completed NCT03051256 - Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD Phase 2
Enrolling by invitation NCT05581797 - Psilocybin-assisted Interpersonal Therapy for Depression N/A
Completed NCT02782104 - A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression Phase 3